SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Czechsinthemail who wrote (83)	9/25/1997 6:42:00 PM
From: scaram(o)uche	of 579

Thanks, Baird. Been knocked offline for a couple of days. IMO, the screening technology is worth the current difference between cash-in-hand and market cap. Gotta keep an eye on the recent "transcription" patent that issued to ONCS, however (I've asked for an assessment by the company, but it was too early for specific comment). Of the biotechs that I screen (many), SIBI appears, to me, to be the most undervalued. I just received the mid-year report. It validates everything that Miljenko and I reported from the annual meeting, but it doesn't give an expected time frame for movement into clinicals of the Bristol-Myers Squibb or Novartis compounds. It specifically names 1553A as the development compound for Alzheimer's dementia (no surprise, but the previous references to "family" had me slightly off-balance). Selected quotes..... "We are seeking a development and marketing partner for SIB-1508Y for the U.S. and Europe as well as a partner for SIB-1553A worldwide." "We expect to advance SIB-1508Y into Phase II clinical trials and SIB-1553A into Phase I studies in the coming months." Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next